BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:peginterferon alfa-2a (Pegasys) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of peginterferon alfa-2a (Pegasys)\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07389044-9776@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:peginterferon alfa-2a (Pegasys): Phase 1 readout est. (NCT07389044)
DESCRIPTION:peginterferon alfa-2a (Pegasys)\, phase 1\, Chronic Hepatitis B
 .\nStudy: A Study on IB-001 Dose Response and Tolerability in Healthy Adul
 ts and Those With Chronic Hepatitis B\nEstimated primary completion: 30 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peginterfer
 on-alfa-2a-pegasys#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07389044
URL:https://assetmemo.bio/drug/peginterferon-alfa-2a-pegasys#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06092333-9776@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:peginterferon alfa-2a (Pegasys): Phase 2 readout est. (NCT06092333)
DESCRIPTION:peginterferon alfa-2a (Pegasys)\, phase 2\, Chronic Hepatitis B
 .\nStudy: VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B\nEsti
 mated primary completion: 29 February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/peginterferon-alfa-2a-pegasys#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06092333
URL:https://assetmemo.bio/drug/peginterferon-alfa-2a-pegasys#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288112-9776@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:peginterferon alfa-2a (Pegasys): Phase 1/2 readout est. (NCT0728811
 2)
DESCRIPTION:peginterferon alfa-2a (Pegasys)\, phase 1/2.\nStudy: DOC1021 De
 ndritic Cell Immunotherapy for Refractory Melanoma\nEstimated primary comp
 letion: January 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /peginterferon-alfa-2a-pegasys#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07288112
URL:https://assetmemo.bio/drug/peginterferon-alfa-2a-pegasys#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
